Evidence of reduced glutamate in the frontal lobe of HIV-seropositive patients

NMR in Biomedicine

Volumn 22, Issue 3, 2009, Pages 326-331

  Sailasuta, Napapon ^a   Shriner, Kimberly ^b   Ross, Brian ^a  

^a HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^b HUNTINGTON MEMORIAL HOSPITAL   (United States)

Author keywords

Central nervous system; Frontal lobe; Glutamate; Highly active retroviral therapy (HAART); HIV; HIV associated dementia; MRS; TE averaged

Indexed keywords

CENTRAL NERVOUS SYSTEM; FRONTAL LOBE; GLUTAMATE; HIGHLY ACTIVE RETROVIRAL THERAPY (HAART); HIV; HIV-ASSOCIATED DEMENTIA; MRS; TE-AVERAGED;

DRUG THERAPY;

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHOLINE; CREATININE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GLUTAMIC ACID; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; N ACETYLASPARTIC ACID; NEUROTRANSMITTER; RITONAVIR; TENOFOVIR DISOPROXIL; ASPARTIC ACID; DRUG DERIVATIVE; N-ACETYLASPARTATE;

ADULT; AMINO ACID BRAIN LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; FRONTAL LOBE; GRAY MATTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NERVOUS SYSTEM INJURY; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; WHITE MATTER; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; VIROLOGY;

ADULT; ASPARTIC ACID; CASE-CONTROL STUDIES; FEMALE; FRONTAL LOBE; GLUTAMIC ACID; HIV SEROPOSITIVITY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED;

EID: 64949177970     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1329     Document Type: Article

References (46)

1. Grant I, McArthur J. HIV neurocognitive disorders. In: The Neurology of AIDS, Gendelman HE, Lipton S, Epstein L, Swindells S (eds). 2nd edn. Oxford University Press: New York, 2005; 000-000.
2. McArthur JC. HIV dementia: an evolving disease. J. Neuroimmunol 2004; 157(1-2): 3-10.
3. Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/ acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J. Neurovirol 2004; 10(6): 350-357.
4. Brew BJ. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 2004; 18 (Suppl 1): S75-78.
5. Letendre SL, McCutchan JA, Childers ME, Woods SP, Lazzaretto D, Heaton RK, Grant I, Ellis RJ. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 2004; 56(3): 416-423.
6. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1(5): 417-422.
7. Vittecoq D, Jardel C, Barthelemy C, Escaut L, Cheminot N, Chapin S, Sternberg D, Maisonobe T, Lombes A. Mitochondrial damage associated with long-term antiretroviral treatment: associated alteration or causal disorder? J Acquir Immune Defic Syndr 2002; 31(3): 299-308.
8. Paley M, Cozzone PJ, Alonso J, Vion-Dury J, Confort-Gouny S, Wilkinson ID, Chong WK, Hall-Craggs MA, Harrison MJ, Gili J, Rovira A, Capellades J, Rio J, Ocana I, Nicoli F, Dhiver C, Gastaut JL, Gastaut JA, Wicklow K, Sauter R. A multicenter proton magnetic resonance spectroscopy study of neurological complications of AIDS. AIDS Res Hum Retroviruses 1996; 12(3): 213-222.
9. Wilkinson ID, Miller RF, Miszkiel KA, Paley MN, Hall-Craggs MA, Baldeweg T, Williams IG, Carter S, Newman SP, Kendall BE, Catalan J, Chinn RJ, Harrison MJ. Cerebral proton magnetic resonance spectroscopy in asymptomatic HIV infection. AIDS 1997; 11(3): 289-295.
10. Yiannoutsos CT, Ernst T, Chang L, Lee PL, Richards T, Marra CM, Meyerhoff DJ, Jarvik JG, Kolson D, Schifitto G, Ellis RJ, Swindells S, Simpson DM, Miller EN, Gonzalez RG, Navia BA. Regional patterns of brain metabolites in AIDS dementia complex. Neuroimage 2004; 23(3): 928-935.
11. Jarvik JG, Lenkinski RE, Grossman RI, Gomori JM, Schnall MD, Frank I. Proton MR spectroscopy of HIV-infected patients: characterization of abnormalities with imaging and clinical correlation. Radiology 1993; 186(3): 739-744.
12. Salvan AM, Vion-Dury J, Confort-Gouny S, Nicoli F, Lamoureux S, Cozzone PJ. Brain proton magnetic resonance spectroscopy in HIV-related encephalopathy: identification of evolving metabolic patterns in relation to dementia and therapy. AIDS Res Hum Retroviruses 1997; 13(12): 1055-1066.
13. Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 2001; 410(6831): 988-994.
14. Kolson DL, Lavi E, Gonzalez-Scarano F. The effects of human immunodeficiency virus in the central nervous system. Adv Virus Res 1998; 50: 1-47.
15. O'Donnell LA, Agrawal A, Jordan-Sciutto KL, Dichter MA, Lynch DR, Kolson DL. Human immunodeficiency virus (HIV)-induced neurotoxicity: roles for the NMDA receptor subtypes. J. Neurosci 2006; 26(3): 981-990.
16. Haughey NJ, Nath A, Mattson MP, Slevin JT, Geiger JD. HIV-1 Tat through phosphorylation of NMDA receptors potentiates glutamate excitotoxicity. J. Neurochem 2001; 78(3): 457-467.
17. Gemignani A, Paudice P, Pittaluga A, Raiteri M. The HIV-1 coat protein gp120 and some of its fragments potently activate native cerebral NMDA receptors mediating neuropeptide release. Eur J Neurosci 2000; 12(8): 2839-2846.
18. Masutani H. Oxidative stress response and signaling in hematological malignancies and HIV infection. Int J Hematol 2000; 71(1): 25-32.
19. Mialocq P, Oiry J, Puy JY, Rimaniol AC, Imbach JL, Dormont D, Clayette P. [Oxidative metabolism of HIV-infected macrophages: the role of glutathione and a pharmacologic approach]. Pathol Biol (Paris) 2001; 49(7): 567-571.
20. Mollace V, Salvemini D, Riley DP, Muscoli C, Iannone M, Granato T, Masuelli L, Modesti A, Rotiroti D, Nistico R, Bertoli A, Perno CF, Aquaro S. The contribution of oxidative stress in apoptosis of human-cultured astroglial cells induced by supernatants of HIV-1-infected macrophages. J. Leukoc Biol 2002; 71(1): 65-72.
21. Turchan J, Pocernich CB, Gairola C, Chauhan A, Schifitto G, Butterfield DA, Buch S, Narayan O, Sinai A, Geiger J, Berger JR, Elford H, Nath A. Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants. Neurology 2003; 60(2): 307-314.
22. Hurd R, Sailasuta N, Srinivasan R, Vigneron DB, Pelletier D, Nelson SJ. Measurement of brain glutamate using TE-averaged PRESS at 3T. Magn Reson Med. 2004; 51(3): 435-440.
23. 1H NMR spectroscopy. J. Magn Reson B 1994; 104(1): 1-10.
24. Brown MA. Time-domain combination of MR spectroscopy data acquired using phased-array coils. Magn Reson Med 2004; 52(5): 1207-1213.
25. Wright SM, Wald LL. Theory and application of array coils in MR spectroscopy. NMR Biomed 1997; 10(8): 394-410.
26. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993; 30(6): 672-679.
27. Fiala M, Murphy T, MacDougall J, Yang W, Luque A, Iruela-Arispe L, Cashman J, Buga G, Byrns RE, Barbaro G, Arthos J. HAART drugs induce mitochondrial damage and intercellular gaps and gp120 causes apoptosis. Cardiovasc Toxicol 2004; 4(4): 327-337.
28. Chang L, Lee PL, Yiannoutsos CT, Ernst T, Marra CM, Richards T, Kolson D, Schifitto G, Jarvik JG, Miller EN, Lenkinski R, Gonzalez G, Navia BA. A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age. Neuroimage 2004; 23(4): 1336-1347.
29. Jarvik JG, Lenkinski RE, Saykin AJ, Jaans A, Frank I. Proton spectroscopy in asymptomatic HIV-infected adults: initial results in a prospective cohort study. J. Acquir Immune Defic Syndr Hum Retrovirol 1996; 13(3): 247-253.
30. Suwanwelaa N, Phanuphak P, Phanthumchinda K, Suwanwela NC, Tantivatana J, Ruxrungtham K, Suttipan J, Wangsuphachart S, Hanvanich M. Magnetic resonance spectroscopy of the brain in neurologically asymptomatic HIV-infected patients. Magn Reson Imaging 2000; 18(7): 859-865.
31. 1H MRS study of the AIDS dementia complex: validation and preliminary analysis. J. Magn Reson Imaging 2003; 17(6): 625-633.
32. Mohamad MSN, Sacktor NC, Skolasky RL, Moxley RT, Pomper MG, Barker PB. 3 Tesla MR spectroscopy reveals decreased glutamate and glutamine levels in frontal white matter in HIV-assoicated dementia. ISMRM 2007; 15: 2140.
33. Chang L, Ernst T, St Hillaire C, Conant K. Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients. Antivir Ther 2004; 9(3): 431-4440.
34. Behar KL, Rothman DL, Spencer DD, Petroff OA. Analysis of macromolecule resonances in 1H NMR spectra of human brain. Magn Reson Med 1994; 32(3): 294-302.
35. Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 2005; 128(Pt 5): 1016-1025.
36. Lentz MR, Westmoreland SV, Lee V, Ratai EM, Halpern EF, Gonzalez RG. Metabolic markers of neuronal injury correlate with SIV CNS disease severity and inoculum in the macaque model of neuroAIDS. Magn Reson Med 2008; 59(3): 475-484.
37. Schweinsburg BC, Taylor MJ, Alhassoon OM, Gonzalez R, Brown GG, Ellis RJ, Letendre S, Videen JS, McCutchan JA, Patterson TL, Grant I. Brain mitochondrial injury in human immunodeficiency virusseropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J. Neurovirol 2005; 11(4): 356-364.
38. Rimaniol AC, Mialocq P, Clayette P, Dormont D, Gras G. Role of glutamate transporters in the regulation of glutathione levels in human macrophages. Am J Physiol Cell Physiol 2001; 281(6): C1964-1970.
39. Chang L, Ernst T, Witt MD, Ames N, Gaiefsky M, Miller E. Relationships among brain metabolites, cognitive function, and viral loads in antiretroviral-naive HIV patients. Neuroimage 2002; 17(3): 1638-1648.
40. Lopez-Villegas D, Lenkinski RE, Frank I. Biochemical changes in the frontal lobe of HIV-infected individuals detected by magnetic resonance spectroscopy. Proc Natl Acad Sci USA 1997; 94(18): 9854-9859.
41. Ernst T, Chang L, Arnold S. Increased glial metabolites predict increased working memory network activation in HIV brain injury. Neuroimage 2003; 19(4): 1686-1693.
42. Keller MA, Venkatraman TN, Thomas MA, Deveikis A, Lopresti C, Hayes J, Berman N, Walot I, Ernst T, Chang L. Cerebral metabolites in HIV-infected children followed for 10 months with 1H-MRS. Neurology 2006; 66(6): 874-879.
43. Erdmann N, Zhao J, Lopez AL, Herek S, Curthoys N, Hexum TD, Tsukamoto T, Ferraris D, Zheng J. Glutamate production by HIV-1 infected human macrophage is blocked by the inhibition of glutaminase. J. Neurochem 2007 102(2): 539-549.
44. Zhao J, Lopez AL, Erichsen D, Herek S, Cotter RL, Curthoys NP, Zheng J. Mitochondrial glutaminase enhances extracellular glutamate production in HIV-1-infected macrophages: linkage to HIV-1 associated dementia. J. Neurochem 2004; 88(1): 169-180.
45. Gras G, Chretien F, Vallat-Decouvelaere AV, Le Pavec G, Porcheray F, Bossuet C, Leone C, Mialocq P, Dereuddre-Bosquet N, Clayette P, Le Grand R, Creminon C, Dormont D, Rimaniol AC, Gray F. Regulated expression of sodium-dependent glutamate transporters and synthetase: a neuroprotective role for activated microglia and macrophages in HIV infection? Brain Pathol 2003; 13(2): 211-222.
46. Choi C, Coupland NJ, Bhardwaj PP, Kalra S, Casault CA, Reid K, Allen PS. T2 measurement and quantification of glutamate in human brain in vivo. Magn Reson Med 2006; 56(5): 971-977.